{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:22Z","timestamp":1794255862719,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.radonc.2026.111821","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:24:07Z","timestamp":1792020247000},"page":"111821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort"],"prefix":"10.1016","volume":"226","author":[{"given":"Ruth","family":"van der Walle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa D.","family":"van Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-5768","authenticated-orcid":false,"given":"Max","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-3028","authenticated-orcid":false,"given":"Mateusz","family":"Bilski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Garlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maris","family":"Mezeckis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kociolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-5195","authenticated-orcid":false,"given":"Frederik R.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulien G.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis A.T.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3020-463X","authenticated-orcid":false,"given":"Wietse S.C.","family":"Eppinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafak","family":"Aluwini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0259-8750","authenticated-orcid":false,"given":"Timo F.W.","family":"Soeterik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.radonc.2026.111821_b0005","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.radonc.2026.111821_b0010","unstructured":"Cornford P. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on prostate cancer 2025 [updated March 2025. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"issue":"5","key":"10.1016\/j.radonc.2026.111821_b0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.radonc.2026.111821_b0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.radonc.2026.111821_b0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","article-title":"Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration","volume":"27","author":"Tang","year":"2026","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.radonc.2026.111821_b0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijrobp.2020.08.030","article-title":"Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer","volume":"109","author":"Deek","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"29","key":"10.1016\/j.radonc.2026.111821_b0035","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2026.111821_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13014-024-02559-7","article-title":"Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Persson","year":"2024","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.radonc.2026.111821_b0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2020.06.029","article-title":"Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?","volume":"150","author":"Franzese","year":"2020","journal-title":"Radiother Oncol."},{"issue":"10","key":"10.1016\/j.radonc.2026.111821_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240892","article-title":"68Ga-PSMA-PET\/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer","volume":"15","author":"Kalinauskaite","year":"2020","journal-title":"PLoS One."},{"issue":"2","key":"10.1016\/j.radonc.2026.111821_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.radonc.2026.111821_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol."},{"issue":"12","key":"10.1016\/j.radonc.2026.111821_b0065","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer."},{"issue":"3","key":"10.1016\/j.radonc.2026.111821_b0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(25)00717-X","article-title":"Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study","volume":"27","author":"Soeterik","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2026.111821_b0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.radonc.2026.111821_b0080","unstructured":"Memorial Sloan Kettering Cancer Center PSA doubling time online calculator [Available from: https:\/\/www.mskcc.org\/nomograms\/prostate\/psa_doubling_time."},{"issue":"4","key":"10.1016\/j.radonc.2026.111821_b0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/sim.4780100410","article-title":"Multiple imputation in health-care databases: an overview and some applications","volume":"10","author":"Rubin","year":"1991","journal-title":"Stat Med."},{"issue":"4","key":"10.1016\/j.radonc.2026.111821_b0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med."},{"issue":"1","key":"10.1016\/j.radonc.2026.111821_b0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clon.2021.10.004","article-title":"Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO\/EORTC Classification in Oligometastatic Bone Disease","volume":"34","author":"Nicholls","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"6","key":"10.1016\/j.radonc.2026.111821_b0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2023.02.010","article-title":"Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy","volume":"6","author":"Milenkovic","year":"2023","journal-title":"Eur Urol Oncol."},{"issue":"6","key":"10.1016\/j.radonc.2026.111821_b0105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.euo.2024.03.010","article-title":"Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer","volume":"7","author":"Deek","year":"2024","journal-title":"Eur Urol Oncol."},{"issue":"10","key":"10.1016\/j.radonc.2026.111821_b0110","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1007\/s00259-020-04760-8","article-title":"Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy","volume":"47","author":"Vogel","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.radonc.2026.111821_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ."},{"issue":"12","key":"10.1016\/j.radonc.2026.111821_b0120","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jclinepi.2015.02.002","article-title":"A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data","volume":"68","author":"Wynants","year":"2015","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"10.1016\/j.radonc.2026.111821_b0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med."},{"key":"10.1016\/j.radonc.2026.111821_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111219","article-title":"Stereotactic ablative body radiotherapy for PSMA-PET\/CT staged, oligometastatic prostate cancer - A multi-centre study","volume":"214","author":"Schupak","year":"2026","journal-title":"Radiother Oncol."},{"issue":"3","key":"10.1016\/j.radonc.2026.111821_b0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2026.111821_b0140","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-022-09523-2","article-title":"Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial","volume":"22","author":"Janssen","year":"2022","journal-title":"BMC Cancer."},{"issue":"2","key":"10.1016\/j.radonc.2026.111821_b0145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijrobp.2025.11.036","article-title":"Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer","volume":"125","author":"Yasar","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:01:16Z","timestamp":1794254476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":29,"alternative-id":["S0167814026006614"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111821","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111821"}}